Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 10/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947020 | 0.92 | MCHR1 (0.49) | GCKNPC1RAB9AMCHR1HPGDS | |
| SCHEMBL944722 | 0.89 | GCK (0.47) | GCKNPC1RAB9AHPGDSKCNH2 | |
| SCHEMBL944042 | 0.88 | GCK (0.46) | GCKNPC1RAB9AMCHR1HPGDS | |
| SCHEMBL980681 | 0.88 | GCK (0.45) | GCKNPC1RAB9AMCHR1HPGDS | |
| SCHEMBL945579 | 0.86 | GCK (0.47) | GCKNPC1RAB9AHPGDSKCNH2 | |
| SCHEMBL944372 | 0.85 | GCK (0.51) | GCKNPC1RAB9AKCNH2 | |
| SCHEMBL946413 | 0.85 | GCK (0.49) | GCKNPC1RAB9AHPGDSKCNH2 | |
| SCHEMBL2669668 | 0.81 | GCK (0.44) | GCKNPC1RAB9AHPGDSKCNH2 | |
| SCHEMBL945739 | 0.81 | GCK (0.44) | GCKNPC1RAB9AHPGDSKCNH2 | |
| SCHEMBL946412 | 0.80 | GCK (0.43) | GCKNPC1RAB9AHPGDSKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2245025-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2245025-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | GLS, GCKR, HK1 | GCK 4/4885NPC1 1995/4885RAB9A 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.